Search

Displaying results 2641 - 2650 of 2955 in total
  1. Drug

    GTS-21

    go.drugbank.com/drugs/DB05708
    Investigational

    controlled study in healthy adults, GTS-21 also demonstrated cognitive enhancement across all doses, with a statistically significant improvement in attention related and memory related tasks (Kitagawa, et

  2. Drug

    VX-702

    go.drugbank.com/drugs/DB05470
    Investigational

    In the future, VX-702 may be investigated for combination with methotrexate, a commonly used therapy for RA. … VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA). It acts as a p38 MAP kinase inhibitor.

  3. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.

  4. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.

  5. Drug

    Pegaspargase

    go.drugbank.com/drugs/DB00059
    ApprovedInvestigational

    [A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927]

    Products: ONCASPAR® 750 U/ML POLVO PARA SOLUCIÓN INYECTABLE, ONCASPAR POWDER FOR SOLUTION FOR INJECTION/INFUSION 750 U/ML
  6. Drug

    Acarbose

    go.drugbank.com/drugs/DB00284
    ApprovedInvestigational

    [L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being [miglitol]), receiving its first FDA approval in 1995 under the brand name Precose (since discontinued

  7. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

  8. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    [A232955, A232960] In September 2023, the FDA also approved cipaglucosidase alfa for similar indications.[L49241]

  9. Drug

    LetibotulinumtoxinA

    go.drugbank.com/drugs/DB16820
    Approved

    [A249920] It was subsequently approved by the FDA in 1992 for use in aesthetic procedures and has since become one of the most popular cosmetic procedures worldwide.

  10. Drug

    Pozelimab

    go.drugbank.com/drugs/DB15218
    ApprovedInvestigational

    [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]